Opsens Inc T.OPS

About Haemonetics...

[bossu]

A solid Company 
Haemonetics Reports Fourth Quarter and Fiscal 2023 Results; Provides Fiscal 2024 Guidance Boston, MA, May 11, 2023 - Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quarter and fiscal 2023, which ended April 1, 2023: 4th Quarter 2023 Fiscal 2023 Revenue, increase $304 million, 15% $1.169 billion, 18% Organic1 revenue increase 17% 21% Earnings per diluted share $0.57 $2.24 Adjusted earnings per diluted share $0.77 $3.03 Cash flow from operating activities $80 million $273 million Free cash flow before restructuring and restructuring related costs $71 million $190 million 1Excludes the impact of currency fluctuation and strategic exits of product lines. Chris Simon, Haemonetics’ CEO, stated: “Our consistently strong results throughout our fiscal year reflect significant progress in accelerating our transformational growth. We are outperforming in a challenging economic environment and meeting the needs of our customers while positioning us for future growth and success.”

What about  another ''BID''  at $ 3,50 or more in the coming weeks,?

Just be patient  for a higher bid for an extra 25 % premium !

[Possibleidiot01]

The desciption of Haemonetics compared to Edwards Lifesciences and Medtronics , two companies more focused on the cardiac market IMO Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and

[francoisl13]

Good point possibleidiot01. Even Abbott Labs and Boston Scientific would be a 'better fit' , at least to me, than Haemonetics. All companies mentioned are much larger in size and more focused on cardiac 'solutions' than Haemonetics. This could end being a good fight between some of the largest players to take control of OPS, time will tell. P.S" For my part, I think that